RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan (SG) for bladder preservation in patients (pts) with muscle invasive bladder cancer (MIBC). A phase 2/3 study of bicycle toxin ...
Three-year median follow-up update of BGB-A317-2002-IIT: A phase 2 study of neoadjuvant tislelizumab plus gemcitabine and cisplatin in patients with cT2–T4aN0M0 muscle-invasive bladder cancer. This is ...
The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), either with or without ...
High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable ...
The American Urological Association (AUA) most recently published guidelines on the management of NMIBC in 2007. 19 These 2007 AUA guidelines set out to address questions only when there was ...
CHICAGO -- An investigational intravesical delivery system designed to provide sustained local release of gemcitabine into the bladder produced high rates of complete response (CR) in ...
SurvivorNet on MSN
Inlexzo: A new option for bladder cancer patients when BCG immunotherapy stops working
If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your ...
"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...
Injections and infusions are a common way to receive chemotherapy. Both methods deliver cancer-treating medications directly into the bloodstream. Chemotherapy is a common cancer treatment that uses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results